GlassScriptPhysician profile
Patrick F Whitney
NPI 1972562767
$2,535.32
in general payments reported to CMS, 2019-2025
26 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2023: $82.01 · 2024: $798 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $452.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $422.07 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $309.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $266.83 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $148.41 | 2019-2025 | Verquvo, Lagevrio, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $119.64 | 2024-2025 | |
| Exact Sciences Corporation | $114.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $89.58 | 2025 | |
| Abbvie INC. | $77.93 | 2025 | |
| Amgen INC. | $68.68 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $61.72 | 2023-2024 | Spravato |
| Pfizer INC. | $59.60 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $57.60 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $38.72 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $29.69 | 2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $28.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.85 | 2019-2024 | Jardiance |
| Bioventus LLC | $22.13 | 2025 | Supartz Fx Sodium Hyaluronate |
| Mylan Specialty L.P. | $20.80 | 2019 | |
| Esperion Therapeutics, INC. | $20.52 | 2024 | Nexletol |
| Averitas Pharma INC. | $19.63 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $15.95 | 2025 | Rexulti |
| Genentech USA, INC. | $15.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.26 | 2024 | Livalo |
| Sumitomo Pharma America, INC. | $13.98 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.